Antonio Di Lorenzo

Dr. Antonio Di Lorenzo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
VGVincenza Gianfredi
Vincenza Gianfredi
ABAlessandro Berti
Alessandro Berti
PSPasquale Stefanizzi
Pasquale Stefanizzi
MDMarilena D’amico
Marilena D’amico
VLViola De Lorenzo
Viola De Lorenzo
SCSilvana Castaldi
Silvana Castaldi
The risk of unfavourable outcomes for SARS-CoV-2 infection is significant during pregnancy and breastfeeding. Vaccination is a safe and effective measure to lower this risk. This study aims at reviewing the literature concerning the anti-SARS-CoV-2 vaccine’s acceptance/hesitancy among pregnant and breastfeeding women attending hospital facilities. A systematic review of literature was carried out. Hospital-based observational studies related to vaccination acceptance, hesitancy, knowledge and attitude among pregnant and breastfeeding women were included. Determinants of acceptance and hesitancy were investigated in detail. Quality assessment was done via the Johann Briggs Institute quality assessment tools. After literature search, 43 studies were included, 30 of which only focused on pregnant women (total sample 25,862 subjects). Sample size ranged from 109 to 7017 people. Acceptance of the SARS-CoV-2 vaccine ranged from 16% to 78.52%; vaccine hesitancy ranged between 91.4% and 24.5%. Fear of adverse events for either the woman, the child, or both, was the main driver for hesitancy. Other determinants of hesitancy included religious concerns, socioeconomic factors, inadequate information regarding the vaccine and lack of trust towards institutions. SARS-CoV-2 vaccine hesitancy in hospitalized pregnant women appears to be significant, and efforts for a more effective communication to these subjects are required.

27 July 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
VGVincenza Gianfredi
Vincenza Gianfredi
PSPasquale Stefanizzi
Pasquale Stefanizzi
ABAlessandro Berti
Alessandro Berti
MDMarilena D’amico
Marilena D’amico
VLViola De Lorenzo
Viola De Lorenzo
SCSilvana Castaldi
Silvana Castaldi
The anti-SARS-CoV-2 vaccination is recommended for pregnant women due to the high risk of complications. However, pregnancy has been associated with vaccine hesitancy. Our review aims at summarizing the existing literature about anti-SARS-CoV-2 vaccine hesitancy in pregnant and lactating women. The research was conducted on PubMed/MEDLINE, ExcerptaMedica Database (EMBASE), and Scopus, according to PRISMA guidelines. Articles regarding the COVID-19 vaccine’s acceptance and/or refusal by pregnant and lactating women were selected. Only observational, population-based studies were included. The Joanna Briggs Institute quality assessment tools were employed. A total of 496 articles were retrieved, and after the selection process, 21 papers were included in the current analysis. All the included studies were cross-sectional, mostly from Europe and North America. The sample sizes ranged between 72 and 25,111 subjects. All of them included pregnant subjects, except one that focused on breastfeeding women only. Vaccine hesitancy rates ranged from 26% to 57% among different studies. Fear of adverse events and lack of knowledge were shown to be the main drivers of hesitancy. Approximately half of the studies (11/21) were classified as low quality, the remaining (9/21) were classified as moderate, and only one study was classified as high quality. Primigravidae were also shown to be more likely to accept anti-SARS-CoV-2 vaccination. Our findings confirm significant anti-SARS-CoV-2 vaccine hesitancy among pregnant women. Information gaps should be addressed to contain concerns related to adverse events.

5 April 2024 in Vaccine
Verified
Journal Article
Open access
PSPasquale Stefanizzi
Pasquale Stefanizzi
LMLorenza Moscara
Lorenza Moscara
CPClaudia Palmieri
Claudia Palmieri
AMAndrea Martinelli
Andrea Martinelli
ALAntonio Di Lorenzo
Antonio Di Lorenzo
Silvio TafuriSilvio Tafuri
Silvio Tafuri
Since 2021 a recombinant adjuvanted anti-Herpes Zoster vaccine(Recombinant Zoster Vaccine, RZV) is offered in Italy to high-risk patients. Few real-life data about RZV safety are available in target populations. This study investigates Adverse Events Following Immunization(AEFIs), baseline disease flare-ups, and Herpes Zoster (HZ) episodes occurring after RZV administration in a heterogeneous population of fragile patients to design its safety profile. This is a retrospective population-based study. RZV-vaccinated patients at Bari Policlinico General Hospital vaccination clinic from October 1st, 2021, to March 31st, 2023, were enrolled. Subjects were screened for reason of RZV eligibility and baseline chronic pathologies. AEFIs occurred in the first 7-days post-vaccination period were collected, and baseline disease flare-ups and post-vaccination HZ episodes were assessed via a 3-month follow-up. Five-hundred-thirty-eight patients were included and total of 1,031 doses were administered. Most patients were vaccinated due to ongoing immunosuppressive therapy(54.65 %); onco-hematological and cardiovascular conditions were the most common chronic baseline pathologies. Out of 1,031 follow-ups, 441 AEFI cases were reported(42.7/100). The most common symptoms were injection site pain/itching(35.60/100), asthenia/malaise(11.44/100), and fever (10.09/100). Four serious AEFIs occurred(0.38/100). Older age, male sex, and history of cardiovascular diseases(OR:0.71; 95CI:0.52-0.98; p-value <0.05) were found to decrease AEFIs risk, while endocrine-metabolic illnesses(OR:1.61; 95CI:1.15-2.26; p-value <0.05) increased it. Twelve patients(2.23 %) reported a flare-up/worsening of their baseline chronic condition within the first three months after vaccination(mean interval 31.75 days, range 0-68 days). Patients with rheumatological illnesses had a higher risk of relapse(OR:16.56; 95CI:3.58-76.56; p-value <0.001), while male sex behaved as a protective factor. Twelve patients who completed the vaccination cycle(2.43%) had at least one HZ episode by the long-term follow-up. The study demonstrates RZV safety in a significant number of high-risk patients. Hence, RZV should be actively offered as part of tailored vaccination programs to decrease the burden of HZ in fragile populations.

10 February 2025 in Journal of Advanced Nursing
Verified
Journal Article
Closed access
DCDania Comparcini
Dania Comparcini
VSValentina Simonetti
Valentina Simonetti
MTMelania Totaro
Melania Totaro
AAAlessia Apicella
Alessia Apicella
FGFrancesco Galli
Francesco Galli
MTMarco Tomietto
Marco Tomietto

Verified
Journal Article
Open access
PDF file
Gianna DipalmaGianna Dipalma
Gianna Dipalma
Alessio Danilo InchingoloAlessio Danilo Inchingolo
Alessio Danilo Inchingolo
FCFilippo Cardarelli
Filippo Cardarelli
ALAntonio Di Lorenzo
Antonio Di Lorenzo
FVFabio Viapiano
Fabio Viapiano
Angelo Michele InchingoloAngelo Michele Inchingolo
Angelo Michele Inchingolo
Objectives: This study aimed to evaluate the effects of AMCOP® elastodontic appliances on cephalometric parameters of skeletal divergence and upper airway dimensions in growing patients, comparing treated individuals with an untreated control group. Methods: A total of 60 subjects (30 treated with AMCOP® devices and 30 controls) were selected, with mean ages of 8.67 ± 1.3 and 9.19 ± 0.8 years, respectively. The AMCOP® appliances, designed for mixed dentition, were worn for 1 h during the day and throughout the night for 6–8 months. Cephalometric analyses were conducted at the beginning (T0) and end (T1) of treatment. Statistical analyses were performed using multivariable linear regression models to assess changes in skeletal and airway parameters, with significance set at p < 0.05. Results: Significant reductions were observed in Ans-Snp^Go-Gn (p = 0.0351), SN^Go-Gn (p = 0.0091), and FMA (p < 0.001) in the treated group compared to controls, indicating improved mandibular rotation. Upper airway spaces (SPAS, MAS, IAS) increased significantly, suggesting enhanced airway patency. Regression models confirmed the positive impact of AMCOP® therapy on skeletal and airway outcomes, particularly in subjects with pronounced vertical discrepancies. Conclusions: AMCOP® elastodontic devices effectively promote anterior mandibular rotation and reduce mandibular plane inclination in hyperdivergent patients, contributing to balanced craniofacial growth. The expansion of pharyngeal spaces indicates potential respiratory benefits. Future research is needed to confirm long-term stability and address variability in treatment response.

9 January 2025 in Applied Nursing Research
Verified
Journal Article
Open access
VSValentina Simonetti
Valentina Simonetti
Giancarlo CicoliniGiancarlo Cicolini
Giancarlo Cicolini
MTMarco Tomietto
Marco Tomietto
BFBarbara Forastefano
Barbara Forastefano
FPFrancesco Pastore
Francesco Pastore
DCDania Comparcini
Dania Comparcini
In Italy, the anti-Human Papillomavirus (HPV) vaccination campaign began in 2008. To date, despite the effectiveness and safety of HPV vaccines, coverage among Italian adolescents is still suboptimal. Evidence suggests that different factors could influence parents' choices regarding their children's vaccination uptake. This study aimed to assess the association of parents' sociodemographic characteristics and vaccine hesitancy with adolescents' perceptions and knowledge of the HPV/HPV vaccine. A cross-sectional study was conducted among Italian students aged 11-13 and their parents. The data were collected by structured questionnaires including sociodemographic questions, the HPV Adolescent Vaccine Intervention Questionnaire (HAVIQ) to assess students' knowledge and perceptions on HPV/HPV vaccination, and the Parent Attitudes about Childhood Vaccines (PACV) Survey to measure parents' vaccine hesitancy. This study involved 74 adolescents and 74 parents. Overall, adolescents showed high levels of confidence in "involvement in decision-making", "self-efficacy", "feelings" and "knowledge" factors of the HAVIQ. 94.6 % of parents were categorized as "non-hesitant" reporting a PACV overall score < 50. Having one or both parents with a university degree in the family was statistically associated with higher students' knowledge (p = 0.048) and lower feelings of fear and anxiety (p = 0.011). This study identified parents' characteristics related to adolescents' knowledge and perceptions regarding the HPV/HPV vaccination. Specifically, results showed that parents' educational level was associated with adolescents' knowledge and feelings about HPV and HPV vaccination. These factors in turn could play a pivotal role in a shared vaccine decision-making process between parents and their children.